Patent intelligence · US
US 12421308
Anti-G-CSF antibodies and uses thereof
Anti-G-CSF antibodies and uses thereof
Patent details — US 12421308
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 23, 2025
- Expiration
- Sep 18, 2045
- Applicant
- ME Therapeutics Inc.
- Claims
- 5
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K39/3955
Quick answer
US 12421308 (Anti-G-CSF antibodies and uses thereof) is held by ME Therapeutics Inc.. Status: granted. Granted Sep 23, 2025. Expires Sep 18, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ME Therapeutics Inc.
- Grant date
- Expiration
- Claims
- 5
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K39/3955, A61P, A61P19/02
More from ME Therapeutics Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12371685
PH20 polypeptide variants with a modification at position 324 of the PH20 polypeptide and a method of making thereof
granted -
US 12264345
PH20 polypeptide variants, formulations and uses thereof
granted -
US 12195773
PH20 polypeptide variants, formulations and uses thereof
granted -
US 12178860
Hyaluronidase enzyme formulations for high volume administration
granted -
US 12152262
PH20 polypeptide variants, formulations and uses thereof
granted -
US 12123035
PH20 polypeptide variants, formulations and uses thereof
granted -
US 12110520
PH20 polypeptide variants, formulations and uses thereof
granted
Frequently asked questions
What is US patent 12421308?
US 12421308 (Anti-G-CSF antibodies and uses thereof) is held by ME Therapeutics Inc.. Status: granted. Granted Sep 23, 2025. Expires Sep 18, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12421308?
ME Therapeutics Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 70 pharmaceutical patents for this assignee.
When does US 12421308 expire?
Our index shows an expiration date of Sep 18, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.